<DOC>
	<DOCNO>NCT00965549</DOCNO>
	<brief_summary>The primary objective demonstrate non-inferiority six month basal plus one insulin regimen ( Lantus plus one injection Apidra ) compare biphasic insulin regimen ( NovoMix 30 ) control glycosylated haemoglobin ( HbA1c ) type 2 diabetes . The secondary objective : - To compare proportion patient treatment group reach HbA1c target ( &lt; 7 % ) end treatment period - To compare rate hypoglycaemia ( total , severe , nocturnal ) - To compare change body weight visit 10 visit 24 - To compare change diabetes specific quality life patient report outcome visit 10 visit 24 - Diabetes Treatment Satisfaction Questionnaire - status change ( DTSQs+c ) - Audit Diabetes-Dependent Quality Life ( ADDQoL ) questionnaire - Insulin Treatment Satisfaction Questionnaire ( ITSQ ) - EuroQoL 5 Dimensions ( EQ5D ) questionnaire - To record change daily dose insulin visit 2 visit 10 visit 10 visit 24</brief_summary>
	<brief_title>Comparison Basal Plus One Insulin Regimen With Biphasic Insulin Regimen Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Protamines</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetes mellitus Patients treat Lantus daily , Levemir twice daily NPH insulin twice daily single insulin least three month 10.0 % &gt; = HbA1c &gt; = 7.5 % BMI &lt; = 40 kg/m² If patient take oral antidiabetic ( OADs ) , dose must stable least 1 month Ability willingness perform blood glucose monitoring use blood glucose meter ability willingness use patient diary Provision write inform obtain prior enrollment study Exclusion criterion : Type 1 diabetes mellitus Current previous treatment insulin basal insulin ( biphasic insulin , short act insulin , rapidacting insulin analogue ) Treatment GLP1 receptor agonist DPPIV inhibitor 3 month screen Active proliferative diabetic retinopathy , define application photocoagulation surgery , 6 month screen unstable ( rapidly progress ) retinopathy may require photocoagulation surgery study ( confirm optic fundus exam perform 2 year prior screen ) Unable unwilling enter either treatment arm Women pregnant lactating ( woman childbearing potential must negative pregnancy test study entry medically approve contraceptive method ) History hypersensitivity study drug drug similar chemical structure Treatment systemic corticosteroid 3 month prior study entry Treatment investigational product 2 month prior study entry Current treatment nonselective betablockers Likelihood require treatment study period drug permit clinical protocol Clinically relevant cardiovascular , hepatic , neurological , endocrine , major disease make implementation protocol interpretation study result difficult Impaired hepatic function show ALT and/or AST great three time upper limit normal screening Impaired renal function show serum creatinine &gt; 135 µmol/l men &gt; 110 µmol/l woman screen History drug alcohol abuse Mental condition render patient unable understand nature , scope possible consequence study Patient unlikely comply protocol , e.g . uncooperative attitude , inability return followup visit , unlikely complete study Patient investigator sub investigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>